Moderna Case Study: the Product is the Personalisation 2026
What mRNA architecture teaches enterprise brands about building digital products at the individual level, and why the most durable competitive advantage in a personalisation-saturated market is not a better recommendation engine.
According to industry research, nine out of ten enterprise firms describe personalisation as imperative to their overall business strategy. More than half of consumers say they do not see their experiences improving, even though they feel like brands are trying to get to know them.
That gap, between the investment brands are making in personalisation and the improvement consumers are actually experiencing, is not primarily a technology problem or a data problem. It is an architectural problem. Most enterprise brands are personalising the wrapper around a standardised product: better-targeted messaging, better-timed offers, better-curated content. The product itself, what the customer actually receives, remains the same for everyone. The personalisation lives in the channel, not in the output.
Moderna made a different decision.
When the company designed mRNA-4157, its individualised cancer vaccine developed with Merck, it did not build a better cancer drug for a defined patient population and then personalise the way it was delivered. It built a manufacturing platform capable of producing a fundamentally different product for every single patient, each dose algorithmically derived from that individual’s unique tumour mutation profile and manufactured in approximately six weeks. The Phase 2b KEYNOTE-942 trial, enrolling 157 patients with stage III/IV melanoma following complete resection, demonstrated a 44% reduction in the risk of disease recurrence or death compared to standard treatment, with updated data showing a 49% reduction in melanoma recurrence and a 62% reduction in distant metastasis risk. The clinical outcome matters. But the strategic lesson is in the architecture that made it possible.
Moderna did not personalise the experience around a product. It personalised the product itself.
The lesson for enterprise brand leaders has nothing to do with oncology.
The Personalisation Ceiling: Why Better Targeting Eventually Stops Producing Better Outcomes
Industry research on enterprise personalisation reveals a structural problem that more investment alone does not solve. The majority of firms direct their personalisation investment at the same architectural approach: better segmentation of a standardised product, delivered through more precisely targeted channels. The logic is internally coherent. Divide customers into meaningful groups, tailor messages and offers to each group, measure whether the tailored approach performs better than the untailored one. It does, usually. But the improvement is bounded by a ceiling that most brands encounter without naming it.
That ceiling arrives at the point where every competitor is using the same data sources, the same platforms, and the same segmentation logic, and the personalisation itself becomes a commodity. When segment-level personalisation is a commodity, the brands that have invested most in it find themselves in a paradox. They have better data than their competitors, faster targeting, more sophisticated lookalike modelling, and they are producing consumer experiences that feel, to the consumer, indistinguishable from what they receive everywhere else. The investment has not produced differentiation. It has produced competitive parity at a higher cost.
In retail, where personalisation investment has been highest and longest-running, brands with sophisticated recommendation engines are discovering that the marginal return on additional personalisation investment has declined to the point where it no longer produces meaningful revenue lift. The market has homogenised around segment-level targeting, and the next meaningful differentiation is not a better recommendation engine. It is a product that is genuinely different for the person who receives it.
This is the question Moderna answered for medicine. It is the question every enterprise brand in retail, financial services, luxury, and healthcare will eventually have to answer for their own product: when the personalisation of the experience around your product stops producing competitive advantage, can you personalise the product itself?
%20(1).png)
Let’s kickstart the conversation and design stuff people will love.
The Retail & Consumer Index
The mRNA-4157 Decision: Designing the Product Around Individual Inputs Rather Than Standardised Outputs
The architecture of mRNA-4157 is the architectural decision this article is about. Moderna did not design a cancer drug and then decide how to deliver it more precisely to different patient populations. It designed a manufacturing system in which the drug itself is the output of an individual-level data process. Each patient’s tumour is sequenced to identify its unique mutational signature. An algorithm selects up to 34 neoantigensL the specific markers that will teach the patient’s immune system to recognise and attack that tumour. A personalised mRNA sequence is constructed and manufactured in approximately six weeks. The result is a product that, by design, cannot be administered to any other patient, because it was built from data that belongs to one person only.
The commercial significance of this architecture is not primarily clinical. It is structural. Moderna’s product strategy in pharma with mRNA-4157 has created a category of one. No competitor can offer the same product, because the product is not a molecule, it is a process. The differentiation lives inside the manufacturing architecture, not in the marketing, the distribution, or the brand. It cannot be replicated through better targeting because there is no targeting involved. There is only individual output.
The parallel to enterprise digital product strategy is specific. Most digital products are built around standardised outputs with personalised presentation: the same product delivered with different content, different sequencing, different visual treatment depending on what segment the user belongs to. The Moderna model asks what it would look like to build the product itself, not the presentation of it, from individual-level data. A financial services product configured to the individual’s actual risk profile and life stage rather than to a demographic segment. A retail experience that generates a different product configuration for each customer rather than a different homepage layout. A healthcare application that produces a different clinical protocol for each patient rather than a different content recommendation.
The gap between personalised presentation and individual product output is the gap Moderna crossed. The question for enterprise brands is whether they are investing to close the same gap.
The Manufacturing Architecture that Makes Individual-Level Output Commercially Sustainable
The most commercially challenging aspect of mRNA-4157 is not the science. It is the manufacturing model. Building a product that is unique to each individual requires a production system that can operate at individual scale without the unit economics that standardised manufacturing depends on. Moderna’s 2024 10-K names this explicitly: its individualised neoantigen therapy product candidates are “uniquely manufactured for each patient using a novel, complex manufacturing process” and the company acknowledges that it “may encounter difficulties in production.” The risk is real. Individual-level manufacturing at commercial scale is a problem that Moderna has not yet fully solved: Phase 3 trials across melanoma, non-small cell lung cancer, and cutaneous squamous cell carcinoma are underway across 20 to 33 countries, and the pathway to commercial-scale individual manufacturing is still being built.
But the direction of the investment is the strategic signal. Moderna is not solving the personalisation problem by improving its segmentation. It is solving it by building the manufacturing infrastructure that makes individual output economically viable. The six-week manufacturing timeline, the algorithmic neoantigen selection, the mRNA synthesis platform that can produce a unique sequence on demand, these are not product features. They are the commercial architecture that individual-level personalisation requires at scale.
The enterprise translation is direct. Individual-level digital product personalisation at scale requires infrastructure investment that segment-level personalisation does not. The data pipelines, the real-time decisioning systems, the product configuration engines, the feedback loops that improve individual output over time, these are the enterprise equivalent of Moderna’s mRNA manufacturing platform. They are expensive, they are complex, and they are not available off the shelf. But they are what separates a digital product that is genuinely different for every user from one that merely appears to be.
The brands that have made this infrastructure investment: Spotify in music discovery, Netflix in content recommendation at the individual rather than segment level, Amazon in product configuration by purchase history, have built structural advantages that brands operating at segment level cannot close through better targeting. The infrastructure is the moat. Moderna is building the same kind of moat in medicine.
The OpenAI Partnership and the Data Infrastructure that Individual-Level Products Require
In 2023, Moderna announced a partnership with OpenAI to integrate generative AI across its drug development and commercial operations. The partnership is not primarily about chatbots or content generation. It is about the data infrastructure that individual-level product manufacturing requires at scale. Moderna’s mRNA platform generates an enormous volume of individual-level biological data: tumour sequencing outputs, neoantigen selection decisions, manufacturing process parameters, clinical response signals. Managing, interpreting, and acting on that data at the speed and volume that individual manufacturing requires is an AI infrastructure problem as much as a biological one.
The parallel to enterprise AI and data evolution strategy is not incidental. Individual-level personalisation at enterprise scale generates individual-level data at a volume and velocity that segment-level operations were never designed to process. The recommendation engine that produces a unique product configuration for each of millions of users in real time requires the same class of AI and data infrastructure that Moderna is building for individual dose manufacturing. The investment in the data layer is not a supporting cost of individual-level personalisation. It is the primary enabling condition.
Moderna’s OpenAI partnership reflects a recognition that individual-level product manufacturing and AI infrastructure are not separate investments, they are the same investment. The mRNA synthesis platform produces the individual product. The AI infrastructure makes the synthesis platform commercially operable at scale. Neither is sufficient without the other. Enterprise brands pursuing individual-level personalisation face the same dependency: the product architecture that makes individual output possible, and the data and AI infrastructure that makes it commercially sustainable.
From Pipeline to Platform: What the Commercial Model Shift Means for Enterprise Brands
Moderna’s mRNA-4157 represents a commercial model shift that has a precise name in the pharmaceutical industry: from pipeline to platform. A pipeline model produces a standardised drug, validates it through clinical trials, and manufactures it at scale for a defined patient population. A platform model produces a process: a manufacturing capability that can generate an unlimited number of unique outputs from individual inputs. The commercial value of a pipeline is bounded by the drug it produces. The commercial value of a platform is bounded only by the number of individuals whose inputs the platform can process.
For enterprise brands, the equivalent shift is from product to product architecture. Most enterprise brands sell a product: a standardised output that is identical for every customer, with personalised presentation around it. The shift Moderna has made is to sell the architecture, a production system whose output is inherently individual. The commercial value of that shift is not just in the product it produces today. It is in the infrastructure it builds for every product the platform will produce in the future.
This is the commercial model decision that enterprise brands can learn from Moderna personalisation ultimately points to. Not a product decision or a technology decision. A model decision: does the brand’s investment in personalisation build a product architecture whose value compounds with every individual interaction, or does it optimise a targeting layer whose marginal returns decline as the competitive environment homogenises? The Moderna model produces individual output that cannot be replicated by a competitor adopting the same targeting approach, because the differentiation lives inside the manufacturing architecture, not in the go-to-market layer around it.
Moderna’s Phase 3 programme across multiple cancer types reflects the platform logic: the same manufacturing architecture that produces an individualised melanoma vaccine can be directed at non-small cell lung cancer, cutaneous squamous cell carcinoma, or any other tumour type whose mutation profile can be sequenced and algorithmically translated into a neoantigen sequence. The platform generates products. The brand builds the platform. This is the distinction that matters for enterprise digital product strategy.
What the Most Personalisation-Saturated Markets are Missing: the Product, not the Wrapper
The markets where personalisation investment has been highest for the longest period are also, not coincidentally, the markets where the personalisation gap is most visible. Retail brands with years of CRM investment and sophisticated recommendation engines are delivering consumer experiences that feel generic. Financial services firms with enormous customer data estates are producing products that feel designed for segments rather than individuals. Luxury brands with detailed client intelligence are offering personalised service that feels scripted rather than genuine. The investment is real. The output is not distinctive.
The Moderna case study suggests a diagnostic for individual-level personalisation product strategy that is more useful than asking whether personalisation is working: ask where the personalisation lives. If it lives in the channel, in the message, the timing, the content selection, the visual treatment, then it is addressing the experience around the product. If it lives in the output, in what the customer actually receives, which is different from what any other customer receives, then it is addressing the product strategy in pharma and enterprise terms that Moderna is demonstrating at the most fundamental level.
Most enterprise brands, if they are honest about where their personalisation investment lives, will find it in the channel. The product they produce is standardised. The presentation around it is personalised. That is not an accusation, it is the rational starting point for personalisation investment, and it produces real returns at the early stages. But it is not where the structural advantage is built. The structural advantage is built by brands that redesign the product itself around individual inputs, that invest in the manufacturing or generation architecture that makes individual output commercially sustainable, and that treat the data infrastructure required to do this not as a supporting cost but as the primary investment.
Moderna made that investment in medicine. The enterprise brands that make the equivalent investment in their own product categories will find, as Moderna has, that the differentiation it produces is of a different kind from what segment-level targeting can generate: it cannot be replicated by a competitor adopting the same targeting approach, because the output itself is the moat.
Executive Takeaways
- Segment-level personalisation produces returns that decline as competitive homogenisation increases, the ceiling is not a technology problem but an architectural one, and it cannot be raised by investing more in the same approach.
- The structural competitive advantage in a personalisation-saturated market is not a better recommendation engine. It is a product architecture whose output is inherently individual, where the differentiation lives inside what the customer receives, not in how it is presented.
- Individual-level product output at commercial scale requires a manufacturing or generation architecture that segment-level operations were not built for, and the investment in that architecture is the primary enabling condition, not a supporting cost.
- The data and AI infrastructure required for individual-level product personalisation is the same class of infrastructure that Moderna is building for individual dose manufacturing, enterprise brands pursuing individual-level output face the same dependency between product architecture and data infrastructure.
- The commercial model shift from product to platform, from standardised output to a production system whose value compounds with every individual interaction, is the strategic decision that separates brands building structural personalisation advantage from those optimising a targeting layer with declining marginal returns.
Why This Matters Now
The personalisation investment cycle that began when enterprise brands first adopted CRM and data management platforms is now old enough to have produced a measurable outcome: industry-wide, the gap between personalisation investment and consumer-perceived personalisation improvement is widening rather than closing. Brands are spending more, and consumers are experiencing less distinction. The infrastructure is better. The output is not more individual. The model, not the technology, is the constraint.
The timing of Moderna’s Phase 3 programme is commercially significant for enterprise brand leaders because it represents the first randomised clinical evidence that individual-level product architecture produces outcomes that segment-level approaches cannot match. The 49% reduction in melanoma recurrence and 62% reduction in distant metastasis risk that mRNA-4157 has demonstrated are not outcomes that a better-targeted standardised drug could produce, because the differentiation that produces those outcomes is inside the product, not around it. For enterprise brands asking whether the investment required to move from segment-level to individual-level product output is commercially justified, the Moderna data is the most direct available answer: individual-level output produces individual-level outcomes that standardised products with personalised presentation cannot replicate.
The enterprise brands that begin making the architectural shift now, from channel personalisation to product personalisation, from targeting investment to product architecture investment, will have a two-to-three year infrastructure advantage over those that recognise the ceiling only after the marginal returns on their current approach have become impossible to ignore. Moderna did not begin building its individual-level manufacturing platform when the demand for personalised medicine became obvious. It began building it when the ceiling of standardised drug development first appeared.
Conclusion
There is a detail in the Moderna story that tends to get lost in the discussion about Phase 2b results and Phase 3 trials. Moderna did not build mRNA-4157 because it had identified a market segment with unmet need and optimised its product for that segment. It built it because it started from a different architectural premise: that the product should be an output of individual data rather than an input to individual targeting. The clinical results: the 44% reduction in recurrence risk, the 62% reduction in distant metastasis, are the commercial proof of that architectural premise, compounded across 157 patients and multiple cancer types. Moderna did not find a better drug. It built a better product architecture.
That is the uncomfortable implication the Moderna case study carries for enterprise brand leaders who are asking whether their personalisation investment is producing the returns it should. The question is not whether the targeting is accurate enough or the data is rich enough or the platform is sophisticated enough. Those are questions about the channel. The question that the Moderna model poses is prior to all of them: is the product itself individual? Because if it is not, if what the customer receives is the same product that every other customer receives, presented through a more precisely targeted channel, then the ceiling on what personalisation can produce is structural, not technical, and it will not be raised by the next platform upgrade or the next data partnership. It will be raised only by the same kind of architectural decision that Moderna made: to redesign the product, not the wrapper.
G&CO. works with enterprise brands in retail, luxury, financial services, and healthcare to design the product architecture and data infrastructure that determine whether personalisation is a marketing layer or a structural competitive advantage. If the Moderna model raises questions about your own digital product strategy and individual-level personalisation investment, submit an inquiry to G&CO. on our contact page or click on the blue “Click to Contact Us” button on the bottom right corner of your screen for your convenience. We look forward to hearing from you.
Frequently asked questions
What is the Moderna product strategy case study about and why does it matter for enterprise brands?
The Moderna product strategy case study examines the architectural decision behind mRNA-4157, Moderna’s individualised cancer vaccine developed with Merck, as a model for enterprise brands evaluating the limits of segment-level personalisation. The case study matters because it demonstrates, through Phase 2b clinical evidence, that individual-level product output produces outcomes that standardised products with personalised presentation cannot replicate. The 44% reduction in melanoma recurrence risk demonstrated in the KEYNOTE-942 trial is not the result of better targeting. It is the result of building a product that is uniquely configured for each individual from their own biological data. The enterprise translation is that the most durable competitive advantage in a personalisation-saturated market is not a better recommendation engine, it is a product architecture whose output is inherently individual.
What can enterprise brands learn from Moderna’s personalisation approach?
What enterprise brands can learn from Moderna’s personalisation approach is the distinction between channel personalisation and individual-level product personalisation, and the architectural and infrastructure investments required to move from the former to the latter. Moderna’s mRNA platform teaches three specific lessons. First, that the competitive ceiling of segment-level personalisation is structural rather than technical and cannot be raised by additional investment in the same approach. Second, that individual-level product output requires a manufacturing or generation architecture that is fundamentally different from segment-level operations, and the investment in that architecture is the primary enabling condition. Third, that the data and AI infrastructure required for individual-level output is not a supporting cost but a co-equal investment with the product architecture itself. Moderna’s OpenAI partnership reflects the same recognition that enterprise brands building individual-level digital product personalisation will need to reach: the product and the data infrastructure are the same investment.
What is individual-level personalisation product strategy and how does it differ from segment-level personalisation?
Individual-level personalisation product strategy is the approach of building products whose output is inherently unique to each individual, generated from individual-level data rather than configured from a standardised template for a defined segment. It differs from segment-level personalisation in the layer at which differentiation is produced. Segment-level personalisation produces differentiation in the channel: the same product is delivered with different messaging, timing, content, or visual treatment depending on the segment the customer belongs to. Individual-level personalisation produces differentiation in the output: what the customer receives is different from what any other customer receives, because it was generated from data that belongs to that individual alone. The commercial significance of this distinction is that individual-level output cannot be replicated by a competitor adopting the same targeting approach, because the differentiation lives inside the product rather than around it.
How does digital product strategy in pharma apply to other enterprise verticals?
The digital product strategy in pharma that Moderna demonstrates with mRNA-4157 applies to enterprise verticals through the principle of individual-level output rather than the specific mechanism of mRNA manufacturing. In retail, the equivalent is a digital product whose configuration, not just its presentation, is generated from individual purchase history, behavioral data, and stated preferences. In financial services, it is a product whose structure reflects the individual’s actual risk profile and life stage rather than a demographic segment assignment. In luxury, it is a client experience whose content and configuration is assembled from individual client intelligence rather than from service scripts calibrated for client tiers. In each case, the architectural requirement is the same: a production or generation system that takes individual inputs and produces individual outputs, supported by data infrastructure that makes the process commercially sustainable at scale. The pharma case is useful precisely because it demonstrates this architecture at the most fundamental level, the product is the biology, and the biology is unique to each person.
What data infrastructure does individual-level personalisation require?
Individual-level personalisation requires data infrastructure of a fundamentally different class from segment-level operations. Segment-level personalisation requires data infrastructure that can assign individual customers to pre-defined groups and deliver group-appropriate content at scale. Individual-level personalisation requires data infrastructure that can process individual-level inputs in real time, generate individual-level outputs on demand, and improve the quality of those outputs through continuous feedback loops at the individual rather than the segment level. In Moderna’s case, this means tumour sequencing infrastructure, algorithmic neoantigen selection, mRNA synthesis platforms, and clinical response monitoring at the individual patient level. In enterprise digital product terms, it means real-time individual behavioral data processing, on-demand product configuration engines, and individual-level outcome tracking that feeds back into the configuration model. The investment required is substantially higher than segment-level personalisation infrastructure, and the partnership Moderna formed with OpenAI reflects the recognition that AI infrastructure is a co-equal component of the individual-level product architecture, not a supplementary tool.
